BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Oct 04, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lixisenatide: Phase III data

Top-line data from the double-blind, Asian Phase III GETGOAL-L-ASIA trial in 311 patients inadequately controlled with basal insulin showed that once-daily lixisenatide as an add-on to basal insulin with or without sulfonylurea met the primary endpoint of significantly reducing HbA1c from baseline to...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >